Bruno Cassinat

List of Publications by Year
in descending order

176 papers	6,452 citations	70961 41 h-index	71532 76 g-index
178 all docs	178 docs citations	178 times ranked	7166 citing authors

#	Article	IF	Citations
1	Revisiting Diagnostic performances of serum erythropoÃ¯etin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement. British Journal of Haematology, 2022, 196, 676-680.	1.2	3
2	Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Advances, 2022, 6, 2813-2823.	2.5	7
3	Reduced intensity hematopoietic stem cell transplantation forÂaccelerated-phase myelofibrosis. Blood Advances, 2022, 6, 1222-1231.	2.5	20
4	Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis. Cells, 2022, 11, 49.	1.8	6
5	CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. Haematologica, 2021, 106, 863-864.	1.7	5
6	Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements. Haematologica, 2021, 106, 1167-1171.	1.7	5
7	Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia, 2021, 35, 871-875.	3.3	10
8	Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 251-252.	1.8	5
9	ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis. International Journal of Molecular Sciences, 2021, 22, 3530.	1.8	3
10	Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transplantation, 2021, 56, 1888-1899.	1.3	18
11	Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Advances, 2021, 5, 1442-1451.	2.5	48
12	Impact of NFE2 mutations on AML transformation andÂoverall survival in patients with myeloproliferative neoplasms. Blood, 2021, 138, 2142-2148.	0.6	23
13	In vitro assessment of the sensitivity to APRâ€246Â+Âazacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients. British Journal of Haematology, 2021, 194, e77-e79.	1.2	2
14	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNÎ± in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	0.6	25
15	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Journal of Experimental Medicine, 2021, 218, .	4.2	22
16	Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis. Blood, 2021, 138, 317-317.	0.6	3
17	Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms. Blood, 2021, 138, 3620-3620.	0.6	1
18	Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French Experience. HemaSphere, 2021, 5, e658.	1.2	2

#	Article	IF	Citations
19	Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia, 2020, 34, 1658-1668.	3.3	14
20	Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses. Haematologica, 2020, 105, e95-e97.	1.7	15
21	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances, 2020, 4, 3708-3715.	2.5	31
22	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744.	2.5	21
23	Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood, 2020, 135, 1032-1043.	0.6	11
24	Pitfalls in CALR exon 9 mutation detection: A singleâ€center experience in 571 positive patients. International Journal of Laboratory Hematology, 2020, 42, 827-832.	0.7	8
25	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. Biology of Blood and Marrow Transplantation, 2020, 26, 1160-1170.	2.0	9
26	Synergistic effects of PRIMA-1^{Met} (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 2020, 105, 1539-1551.	1.7	101
27	Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms. Cancers, 2020, 12, 992.	1.7	10
28	MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491. Blood, 2020, 135, 948-953.	0.6	16
29	Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission. Blood, 2020, 136, 35-36.	0.6	16
30	JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators. Blood, 2020, 136, 4-5.	0.6	0
31	SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). Blood, 2020, 136, 1-1.	0.6	4
32	Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF). Blood, 2020, 136, 8-8.	0.6	2
33	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. European Journal of Haematology, 2019, 103, 552-557.	1.1	12
34	How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?. Expert Review of Hematology, 2019, 12, 473-476.	1.0	3
35	Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S107-S108.	2.0	0
36	When hemolysis masks polycythemia vera. Clinical Case Reports (discontinued), 2019, 7, 438-441.	0.2	1

#	Article	IF	Citations
37	Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. Blood, 2019, 133, 1766-1777.	0.6	23
38	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood, 2019, 133, 2233-2242.	0.6	121
39	Exome analysis of treatmentâ€related <scp>AML</scp> after <scp>APL</scp> suggests secondary evolution. British Journal of Haematology, 2019, 185, 984-987.	1.2	1
40	International external quality assurance of JAK2 V617F quantification. Annals of Hematology, 2019, 98, 1111-1118.	0.8	3
41	Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls. Annals of Hematology, 2019, 98, 111-118.	0.8	16
42	Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses. Blood, 2019, 134, 836-836.	0.6	1
43	S1610ÂMASKED POLYCYTHEMIA VERA: ANALYSIS OF A SINGLE CENTER SERIES OF 2480 RED CELL MASSES.. HemaSphere, 2019, 3, 742.	1.2	0
44	Impact of hydroxycarbamide and interferon-Î± on red cell adhesion and membrane protein expression in polycythemia vera. Haematologica, 2018, 103, 972-981.	1.7	11
45	Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer Journal, 2018, 8, 94.	2.8	34
46	Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nature Communications, 2018, 9, 2047.	5.8	35
47	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia, 2018, 32, 2066-2069.	3.3	4
48	Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features. Thrombosis and Haemostasis, 2018, 118, 1586-1599.	1.8	60
49	Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 689-689.	0.6	6
50	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	1.8	50
51	The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia, 2017, 31, 1661-1670.	3.3	83
52	Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET. Journal of Nuclear Medicine, 2017, 58, 1603-1608.	2.8	14
53	Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2^{V617F} mutation. Haematologica, 2017, 102, e241-e244.	1.7	10
54	Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone. Leukemia and Lymphoma, 2017, 58, 749-751.	0.6	4

#	Article	IF	Citations
55	New chimeric RNAs in acute myeloid leukemia. F1000Research, 2017, 6, 1302.	0.8	8
56	New chimeric RNAs in acute myeloid leukemia. F1000Research, 2017, 6, 1302.	0.8	9
57	Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1206-1211.	2.0	70
58	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. International Immunopharmacology, 2016, 40, 466-473.	1.7	25
59	Unexplained thrombocytosis: association of Baltimore polymorphism with germline <scp>MPL</scp> nonsense mutation. British Journal of Haematology, 2016, 175, 167-169.	1.2	3
60	Quantification of the Mutant CALR Allelic Burden by Digital PCR. Journal of Molecular Diagnostics, 2016, 18, 68-74.	1.2	30
61	Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia, 2016, 30, 776-781.	3.3	109
62	Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia. Blood, 2016, 128, 2892-2892.	0.6	1
63	Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. Blood, 2016, 128, 2861-2861.	0.6	0
64	Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms. Blood, 2016, 128, 1941-1941.	0.6	0
65	JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics. Blood, 2016, 128, 4273-4273.	0.6	0
66	Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation. Blood, 2016, 128, 3106-3106.	0.6	0
67	Clinical and molecular response to interferon-Î± therapy in essential thrombocythemia patients with CALR mutations. Blood, 2015, 126, 2585-2591.	0.6	127
68	Lu/BCAMâ€•mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients. American Journal of Hematology, 2015, 90, E137-8.	2.0	6
69	Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent. Leukemia, 2015, 29, 2277-2284.	3.3	19
70	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia, 2015, 29, 1084-1091.	3.3	70
71	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nature Genetics, 2015, 47, 1334-1340.	9.4	152
72	Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm. Thrombosis Research, 2015, 136, 839-840.	0.8	5

#	Article	IF	Citations
73	Establishment of Acute Myeloid Leukemic Xenografts as Preclinical Models of Epigenetic Therapies. International Journal of Hematology Research, 2015, 1, 79-89.	0.2	0
74	Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins. PLoS ONE, 2015, 10, e0129222.	1.1	0
75	Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia. New England Journal of Medicine, 2014, 371, 188-189.	13.9	67
76	<scp>TET</scp>2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis. British Journal of Haematology, 2014, 165, 416-419.	1.2	1
77	Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNÎ± treatment. Leukemia, 2014, 28, 460-463.	3.3	12
78	Juvenile myelomonocytic leukaemia and Noonan syndrome. Journal of Medical Genetics, 2014, 51, 689-697.	1.5	112
79	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. European Journal of Cancer, 2014, 50, 1159-1168.	1.3	24
80	Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms. Blood, 2014, 123, 794-796.	0.6	13
81	Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis (FLT-MF-2009 Study). Blood, 2014, 124, 3195-3195.	0.6	1
82	Targeted Exome Sequencing Identifies Novel Mutations in Familial Myeloproliferative Neoplasms Patients in the State of Qatar. Blood, 2014, 124, 5570-5570.	0.6	2
83	Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?. Blood, 2014, 124, 3200-3200.	0.6	0
84	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 2013, 27, 2032-2039.	3.3	96
85	Quantification of JAK2V617F mutation by next-generation sequencing technology. American Journal of Hematology, 2013, 88, 536-537.	2.0	9
86	Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. Leukemia Research, 2013, 37, 312-319.	0.4	5
87	Tracking the extramedullary PML-RARÎ±-positive cell reservoirs in a preclinical model: Biomarker of long-term drug efficacy. Molecular and Cellular Probes, 2013, 27, 1-5.	0.9	7
88	Longâ€term followâ€up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology, 2013, 88, 556-559.	2.0	30
89	In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. Leukemia, 2013, 27, 2404-2407.	3.3	23
90	JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood, 2013, 121, 658-665.	0.6	88

#	Article	IF	Citations
91	Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica, 2013, 98, 1517-1524.	1.7	45
92	Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc. Blood, 2013, 122, 306-306.	0.6	50
93	Familial Essential Thrombocythemia Among Qatari Tribes. Blood, 2013, 122, 5244-5244.	0.6	5
94	AOP2014/P1101, a Novel Peg-Proline-Interferon Alpha (IFNa) 2b, Specifically Targets JAK2V617F-Positive Polycythemia Vera (PV) Cells. Blood, 2013, 122, 1611-1611.	0.6	0
95	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group. Journal of Clinical Oncology, 2012, 30, 1641-1646.	0.8	49
96	Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2RÎ³â^'/â^' mice. Leukemia, 2012, 26, 2432-2435.	3.3	17
97	Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number. Blood Cancer Journal, 2012, 2, e66-e66.	2.8	9
98	Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?. Blood Cancer Journal, 2012, 2, e70-e70.	2.8	4
99	Bexarotene via CBP/p300 Induces Suppression of NF-ÎºBâ€“Dependent Cell Growth and Invasion in Thyroid Cancer. Clinical Cancer Research, 2012, 18, 442-453.	3.2	28
100	Live and let (MPN cells) die!. Blood, 2012, 120, 2933-2934.	0.6	0
101	Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. Cellular Signalling, 2012, 24, 2369-2377.	1.7	47
102	Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient. American Journal of Hematology, 2012, 87, 646-646.	2.0	1
103	The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood, 2011, 117, 5777-5778.	0.6	13
104	Neurological disorders in essential thrombocythemia. Haematologica, 2011, 96, 1866-1869.	1.7	16
105	Identification of JAK2 mutations in canine primary polycythemia. Experimental Hematology, 2011, 39, 542-545.	0.2	23
106	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. Leukemia Research, 2011, 35, 863-867.	0.4	44
107	Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2011, 46, 557-561.	1.3	19
108	New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor Î± Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation. Molecular and Cellular Biology, 2011, 31, 1409-1418.	1.1	23

#	Article	IF	Citations
109	Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon Î±-2a (peg-IFNÎ±-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial. Blood, 2011, 118, 280-280.	0.6	8
110	Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study. Blood, 2011, 118, 2812-2812.	0.6	2
111	AK2 Regulates Hematopoietic Cell Survival, Proliferation and Differentiation Along the T-Cell and Neutrophil Lineages. Blood, 2011, 118, 1315-1315.	0.6	1
112	Expression level and differential JAK2-V617Fâ€“binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood, 2010, 116, 5961-5971.	0.6	51
113	Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 460-468.	1.2	64
114	PMLâ€“RARÎ± ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL. Leukemia, 2010, 24, 473-476.	3.3	16
115	Clonal analysis of erythroid progenitors suggests that pegylated interferon Î±-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia, 2010, 24, 1519-1523.	3.3	79
116	Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. Journal of Medical Genetics, 2010, 47, 686-691.	1.5	125
117	Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients. PLoS ONE, 2010, 5, e8893.	1.1	27
118	Lack of Association Between the 46/1 JAK2 Haplotype and the Presence of JAK2V617F Mutation In Splanchnic Vein Thrombosis Patients. Blood, 2010, 116, 4120-4120.	0.6	0
119	Screening for JAK2V617F and MPL515 Mutations in Idiopathic Pulmonary Fibrosis.. , 2009, , .		0
120	Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica, 2009, 94, 487-495.	1.7	77
121	P126 Treatment of progression of myeloproliferative neoplasm (MPN) to MDS/AML by azacytidine (AZA): a report on 44 patients (pts). Leukemia Research, 2009, 33, S132-S133.	0.4	0
122	When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). Leukemia Research, 2009, 33, 1178-1182.	0.4	14
123	Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood, 2009, 113, 412-421.	0.6	97
124	Human Adenylate Kinase 2 Deficiency Inhibits Hematopoietic Cell Differentiation towards Neutrophil and T Lymphoid Lineages.. Blood, 2009, 114, 78-78.	0.6	0
125	Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?. Leukemia, 2008, 22, 452-453.	3.3	41
126	HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia, 2008, 22, 578-584.	3.3	24

#	Article	IF	Citations
127	Mutations in exon 12 of JAK2 are mainly found in JAK2 V617Fâ€negative polycythaemia vera patients. British Journal of Haematology, 2008, 142, 676-679.	1.2	24
128	Auer rods and differentiation in acute promyelocytic leukemia. British Journal of Haematology, 2008, 142, 998-1000.	1.2	3
129	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood, 2008, 111, 4922-4929.	0.6	319
130	Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 2008, 112, 3065-3072.	0.6	511
131	The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thrombosis and Haemostasis, 2008, 99, 1119-1120.	1.8	20
132	Treatment of Progression of Myeloproliferative Disorders(MPD) to MDS/AML by Azacytidine (AZA) : A Preliminary Report on 17 Patients (pts). Blood, 2008, 112, 2800-2800.	0.6	1
133	Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood, 2007, 109, 4450-4460.	0.6	33
134	Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. European Journal of Cancer, 2007, 43, 816-821.	1.3	31
135	Epigenetic patterns of the retinoic acid receptor Î²2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene, 2007, 26, 4018-4024.	2.6	36
136	The V617F JAK2 mutation and the increase in platelet CD36 in essential thrombocythemia are unrelated events. European Journal of Haematology, 2007, 79, 269-270.	1.1	0
137	High molecular response rate of polycythemia vera patients treated with pegylated interferon Â-2a. Blood, 2006, 108, 2037-2040.	0.6	240
138	Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporineâ€“sirolimus interaction. Kidney International, 2006, 70, 1019-1025.	2.6	102
139	Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia, 2006, 20, 1181-1183.	3.3	45
140	The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, 2006, 20, 1319-1321.	3.3	92
141	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.. Blood, 2006, 108, 377-377.	0.6	8
142	The Challenge of Diagnosing Fanconi Anemia in Patients with Bone Marrow Failure (BMF): A Study in 82 BMF Patients.. Blood, 2006, 108, 991-991.	0.6	4
143	The JAK2 V617F Mutation Identifies Specific Subgroups of Myelodysplastic Syndrome (MDS).. Blood, 2006, 108, 2610-2610.	0.6	0
144	Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Blood, 2005, 105, 3743-3745.	0.6	5

#	Article	IF	Citations
145	Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia, 2005, 19, 1153-1160.	3.3	134
146	A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation. Cancer Genetics and Cytogenetics, 2005, 159, 69-73.	1.0	14
147	DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia. New England Journal of Medicine, 2005, 352, 1529-1538.	13.9	262
148	Inhibitory Activity of Human Immunodeficiency Virus Aspartyl Protease Inhibitors against Encephalitozoon intestinalis Evaluated by Cell Culture-Quantitative PCR Assay. Antimicrobial Agents and Chemotherapy, 2005, 49, 2362-2366.	1.4	11
149	Analysis of JAK2 Mutation in Essential Thrombocythemia (ET) Patients with Monoclonal and Polyclonal X-Chromosome Inactivation Patterns (XCIPs).. Blood, 2005, 106, 2603-2603.	0.6	2
150	All Trans Retinoic Acid (atRA) Differentiation Markers in Normal and Retinoid-Resistant Acute Promyelocytic Leukemia Cells Revealed Induction of atRA Metabolism as Relevant Prognostic of APL Sensitivity to Therapy.. Blood, 2005, 106, 3256-3256.	0.6	2
151	PVN1: A Phase 2 Study of Pegylated Interferon-Î±2a in Polycythemia Vera (PV) by the â€œPV-Nordâ€•Group. Preliminary Report of Efficacy and Safety.. Blood, 2005, 106, 4940-4940.	0.6	1
152	Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register. Leukemia, 2004, 18, 1553-1555.	3.3	30
153	Overcoming bacterial DNA contamination in real-time PCR and RT-PCR reactions for LacZ detection in cell therapy monitoring. Molecular and Cellular Probes, 2004, 18, 437-441.	0.9	12
154	Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood, 2004, 103, 4119-4125.	0.6	187
155	Development of a Real-Time PCR Assay for Quantitative Detection of Encephalitozoon intestinalis DNA. Journal of Clinical Microbiology, 2003, 41, 1410-1413.	1.8	51
156	Development of a Realâ€Time Polymeraseâ€Chainâ€Reaction Assay for Quantitative Detection ofEnterocytozoon bieneusiDNA in Stool Specimens from Immunocompromised Patients with Intestinal Microsporidiosis. Journal of Infectious Diseases, 2003, 187, 1469-1474.	1.9	64
157	Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2003, 21, 2326-2334.	0.8	146
158	Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrology Dialysis Transplantation, 2003, 18, 2409-2414.	0.4	149
159	Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2003, 14, 1889-1896.	3.0	257
160	Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2. Transplantation, 2003, 76, 1233-1235.	0.5	257
161	Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood, 2002, 99, 2615-2616.	0.6	30
162	Dosage du 27â€“29 sur AIA 600 IIÂ® Tosoh-BioscienceÂ: Ã‰valuation analytique et comparaison avec le dosage de CA 15-3 KryptorÂ® (Brahms). Immuno-Analyse Et Biologie Specialisee, 2002, 17, 401-406.	0.0	2

#	Article	IF	Citations
163	Dosages de NSE et protÃ©ine S-100 dans le liquide cÃ©phalorachidien (LCR). Immuno-Analyse Et Biologie Specialisee, 2002, 17, 407-411.	0.0	0
164	Sequence Analysis Identifies TTRAP, a Protein That Associates with CD40 and TNF Receptor-Associated Factors, as a Member of a Superfamily of Divalent Cation-Dependent Phosphodiesterases. Biochemical and Biophysical Research Communications, 2001, 285, 1274-1279.	1.0	26
165	Future perspectives for acute promyelocytic leukemia therapy. Seminars in Hematology, 2001, 38, 86-91.	1.8	2
166	In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood, 2001, 98, 2862-2864.	0.6	36
167	Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management. Oncogene, 2001, 20, 7154-7160.	2.6	15
168	Future perspectives for acute promyelocytic leukemia therapy. Seminars in Hematology, 2001, 38, 86-91.	1.8	3
169	Intermethod discordance for alpha-fetoprotein measurements in Fanconi anemia. Clinical Chemistry, 2001, 47, 1405-9.	1.5	1
170	Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia, 2000, 14, 324-328.	3.3	116
171	Response. Leukemia, 2000, 14, 1531-1531.	3.3	0
172	From guidelines to hospital practice: reducing inappropriate ordering of thyroid hormone and antibody tests. European Journal of Endocrinology, 2000, 142, 605-610.	1.9	22
173	Co-expression and secretion of C3, the third component of complement and a C3-cleaving cysteine proteinase in a highly metastatic human melanoma cell line. Immunology Letters, 1997, 58, 107-112.	1.1	12
174	Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. European Journal of Immunology, 1995, 25, 2661-2667.	1.6	12
175	Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2. Molecular Immunology, 1995, 32, 1295-1298.	1.0	7
176	Comparison of antibiotic combinations against penicillin-resistant pneumococci. Journal of Antimicrobial Chemotherapy, 1994, 34, 785-790.	1.3	14